CD40 ligand in CLL pathogenesis and therapy

Leukemia and Lymphoma

Volumn 37, Issue 5-6, 2000, Pages 461-472

  Schattner, Elaine J ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Apoptosis; B cells; CD40; Chronic lymphocytic leukemia; T cells

Indexed keywords

ANTIBODY; CD40 ANTIGEN; CLADRIBINE; FLUDARABINE PHOSPHATE; GLYCOPROTEIN GP 39; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; CD40 LIGAND; TUMOR ANTIGEN; TUMOR PROTEIN;

ANTIGEN ANTIBODY REACTION; AUTOIMMUNITY; B LYMPHOCYTE DIFFERENTIATION; CANCER IMMUNOLOGY; CELL SURVIVAL; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; IMPEDANCE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TUMOR GROWTH; APOPTOSIS; AUTOCRINE EFFECT; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BIOLOGICAL MODEL; CANCER STEM CELL; CD4+ T LYMPHOCYTE; GENETICS; IMMUNOLOGY; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LYMPHOCYTE FUNCTION; METABOLISM; PARACRINE SIGNALING; PATHOLOGY; PHYSIOLOGY;

ANTIGENS, CD40; ANTIGENS, NEOPLASM; APOPTOSIS; AUTOCRINE COMMUNICATION; AUTOIMMUNE DISEASES; B-LYMPHOCYTE SUBSETS; CD4-POSITIVE T-LYMPHOCYTES; CD40 LIGAND; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKEMIA, LYMPHOCYTIC, CHRONIC; LYMPHOCYTE COOPERATION; MODELS, BIOLOGICAL; NEOPLASM PROTEINS; NF-KAPPA B; PARACRINE COMMUNICATION; TUMOR STEM CELLS;

EID: 0034005455     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.3109/10428190009058499     Document Type: Review

References (113)

1. Kipps TJ, Carson DA. (1993) Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 81, 2475-87.
2. Caligaris-Cappio F. (1996) B-chronic lymphocytic leukemia: a malignancy of anti-self B cells. Blood 87, 2615-20.
3. Kantor A. (1991) A new nomenclature for B cells. Immunol Today 12, 388.
4. Hardy RR, Li YS, Hayakawa K. (1996) Distinctive developmental origins and specificities of the CD5+ B-cell subset. Semin Immunol 8, 37-44.
5. Casali P, Burastero SE, Nakamura M, Inghirami G, Notkins AL. (1987) Human lymphocytes making rheumatoid factor and antibody to ssDNA belong to Leu-1+ B-cell subset. Science 236, 77-81.
6. Diaw L, Magnac C, Pritsch O, Buckle M, Alzari PM, Dighiero G. (1997) Structural and affinity studies of IgM polyreactive natural autoantibodies. J Immunol 158, 968-76.
7. Hayakawa K, Asano M, Shinton SA, Gui M, Allman D, Stewart CL, Silver J, Hardy RR. (1999) Positive selection of natural autoreactive B cells. Science 285, 113-6.
8. Durandy A, Thuillier L, Forveille M, Fischer A. (1990) Phenotypic and functional characteristics of human newborns' B lymphocytes. J Immunol 144, 60-5.
9. Kasaian MT, Casali P. (1993) Autoimmunity-prone B-1 (CD5 B) cells, natural antibodies and self recognition. Autoimmunity 15, 315-29.
10. Diehl LF, Ketchum LH. (1998) Autoimmune disease and chronic lymphocytic leukemia: autoimmune hemolytic anemia, pure red cell aplasia, and autoimmune thrombocytopenia. Semin Oncol 25, 80-97.
11. Pritsch O, Maloum K, Dighiero G. (1998) Basic biology of autoimmune phenomena in chronic lymphocytic leukemia. Semin Oncol 25, 34-41.
12. Fu SM, Chiorazzi N, Kunkel HG, Halper JP, Harris SR. (1978) Induction of in vitro differentiation and immunoglobulin synthesis of human leukemic B lymphocytes. Journal of Experimental Medicine 148, 1570-8.
13. Fu SM, Chiorazzi N, Kunkel HG. (1979) Differentiation capacity and other properties of the leukemic cells of chronic lymphocytic leukemia, Immunological Reviews 48, 23-44.
14. Johnstone AP, Jensenius JC, Millard RE, Hudson L. (1982) Mitogen-slimulated immunoglobulin production by chronic lymphocylic leukaemic lymphocytes. Clinical & Experimental Immunology 47, 697-705.
15. Sthoeger ZM, Wakai M, Tse DB, Vinciguerra VP, Allen SL, Budman DR, Lichtman SM, Schulman P, Weiselberg LR, Chiorazzi N. (1989) Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia. Journal of Experimental Medicine 169, 255-68.
16. Schroeder HW, Jr., Dighiero G. (1994) The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 15, 288-94.
17. Fais F, Sellars B, Ghiotto F, Yan XJ, Dono M, Allen SL, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Schuster M, Vinciguerra VP, Rai K, Stevenson FK, Gregersen PK, Ferrarini M, Chiorazzi N. (1996) Examples of in vivo isotype class switching in IgM+ chronic lymphocytic leukemia B cells. J Clin Invest 98, 1659-66.
18. Malisan F, Fluckiger AC, Ho S, Guret C, Banchereau J, Martinez-Valdez H. (1996) B-chronic lymphocytic leukemias can undergo isotype switching in vivo and can be induced to differentiate and switch in vitro. Blood 87, 717-24.
19. Ledbetter JA, Shu G, Gallagher M, Clark EA. (1987) Augmentation of normal and malignant B cell proliferation by monoclonal antibody to the B cell-specific antigen BP50 (CDW40). Journal of Immunology 138, 788-94.
20. Stamenkovic I, Clark EA, Seed B. (1989) A B-lymphocyte activation molecule related to the nerve growth factor receptor and induced by cytokines in carcinomas. EMBO Journal 8, 1403-10.
21. van Kooten C, Banchereau J. (1997) Functions of CD40 on B cells, dendritic cells and other cells. Curr Opin Immunol 9, 330-7.
22. Noelle RJ, Roy M, Shepherd DM, Stamenkovic I, Ledbetter JA, Aruffo A. (1992) A 39-kDa protein on activated helper T cells binds CD40 and transduces the signal for cognate activation of B cells. Proc Natl Acad Sci U S A 89, 6550-4.
23. Graf D, Korthauer U, Mages HW, Senger G, Kroczek RA. (1992) Cloning of TRAP, a ligand for CD40 on human T cells. Eur J Immunol 22, 3191-4.
24. Lederman S, Yellin MJ, Krichevsky A, Belko J, Lee JJ, Chess L. (1992) Identification of a novel surface protein on activated CD4+ T cells that induces contact-dependent B cell differentiation (help). Journal of Experimental Medicine 175, 1091-101.
25. Spriggs MK, Armitage RJ, Strockbine L, Clifford KN, Macduff BM, Sato TA, Maliszewski CR, Fanslow WC. (1992) Recombinant human CD40 ligand stimulates B cell proliferation and immunoglobulin E secretion. J Exp Med 176, 1543-50.
26. Liu YJ, Joshua DE, Williams GT, Smith CA, Gordon J, MacLennan IC. (1989) Mechanism of antigen-driven selection in germinal centres. Nature 342, 929-31.
27. Banchereau J, de Paoli P, Valle A, Garcia E, Rousset F. (1991) Long-term human B cell lines dependent on interleukin-4 and antibody to CD40. Science 251, 70-2.
28. Lederman S, Yellin MJ, Cleary AM, Pernis A, Inghirami G, Conn LE, Covey LR, Lee JJ, Rothman P, Chess L. (1994) T-BAM/CD40-L on helper T lymphocytes augments lymphokine-induced B cell Ig isotype switch recombination and rescues B cells from programmed cell death. Journal of Immunology 152, 2163-71.
29. Ranheim EA, Kipps TJ. (1993) Activated T cells induce expression of B7/BB1 on normal or leukemic B cells through a CD40-dependent signal. J Exp Med 177, 925-35.
30. Saeland S, Duvert V, Moreau I, Banchereau J. (1993) Human B cell precursors proliferate and express CD23 after CD40 ligation. Journal of Experimental Medicine 178, 113-20.
31. Rothstein TL, Wang JK, Panka DJ, Foote LC, Wang Z, Stanger B, Cui H, Ju ST, Marshak-Rothstein A. (1995) Protection against Fas-dependent Thl-mediated apoptosis by antigen receptor engagement in B cells. Nature 374, 163-5.
32. Schattner EJ, Elkon KB, Yoo DH, Tumang J, Krammer PH, Crow MK, Friedman SM. (1995) CD40 ligation induces Apo-1/Fas expression on human B lymphocytes and facilitates apoptosis through the Apo-1/Fas pathway. Journal of Experimental Medicine 182, 1557-65.
33. Garrone P, Neidhardt EM, Garcia E, Galibert L, van Kooten C, Banchereau J. (1995) Fas ligation induces apoptosis of CD40-activated human B lymphocytes. Journal of Experimental Medicine 182, 1265-73.
34. Lalmanach-Girard AC, Chiles TC, Parker DC, Rothstein TL. (1993) T cell-dependent induction of NF-kappa B in B cells. J Exp Med 177, 1215-9.
35. Berberich I, Shu GL, Clark EA. (1994) Cross-linking CD40 on B cells rapidly activates nuclear factor-kappa B. J Immunol 153, 4357-66.
36. Grumont RJ, Rourke IJ, Gerondakis S. (1999) Rel-dependent induction of Al transcription is required to protect B cells from antigen receptor ligation-induced apoptosis. Genes Dev 13, 400-11.
37. Dighiero G, Kipps T, Schroeder HW, Chiorazzi N, Stevenson F. Silberstein LE, Caligaris-Cappio F, Ferrarini M. (1996) What is the CLL B-lymphocyte? Leuk Lymphoma 2, 13-39.
38. Andreeff M, Darzynkiewicz Z, Sharpless TK, Clarkson BD, Melamed MR. (1980) Discrimination of human leukemia subtypes by flow cytometric analysis of cellular DNA and RNA. Blood 55, 282-93.
39. Harris NL, Jaffe ES, Stein H, Banks PM, Chan JK, Cleary ML, Delsol G, De Wolf-Peeters C, Falini B, Gatter KC, Grogan TM, Isaacson PG, Knowles DM, Mason DY, Muller-Hermelink H.K., Pileri SA, Piris MA, Ralfkiaer E, Warnke RA. (1994) A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 84, 1361-92.
40. Gregory CD, Tursz T, Edwards CF, Tetaud C, Talbot M, Caillou B, Rickinson AB, Lipinski M. (1987) Identification of a subset of normal B cells with a Burkitt's lymphoma (BL)-like phenotype. Journal of Immunology 139, 313-8.
41. Klein G. (1994) Epstein-Barr virus strategy in normal and neoplastic B cells. Cell 77, 791-3.
42. Schattner EJ, Mascarenhas J, Reyfman I, Koshy M, Woo C, Friedman SM, Crow MK. (1998) Chronic lymphocytic leukemia B cells can express CD40 ligand and demonstrate T-cell type costimulatory capacity. Blood 91, 2689-97.
43. Trentin L, Zambello R, Sancetta R, Facco M, Cerutti A, Perin A, Siviero M, Basso U, Bortolin M, Adami F, Agostini C, Semenzato G. (1997) B lymphocytes from patients with chronic lymphoproliferative disorders are equipped with different costimulatory molecules. Cancer Research 57, 4940-7.
44. Clodi K, Asgary Z, Zhao S, Kliche K-O, Cabanillas F, Andreeff M, Younes A. (1998) Coexpression of CD40 and CD40 ligand in B-cell lymphoma cells. British Journal of Haematology 103, 270-5.
45. Wasil T, Damle RN, Allen SL, Buchbinder A, Kittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra V, Rai KR, Chiorazzi N. Overexpression of CD40L on the b and T cells of chronic lymphocytic leukemia patients with autoimmune phenomena, Proceedings of ASCO, May, 1998. (Vol. 17). American Society of Clinical Oncology.
46. Wykes M, Poudrier J, Lindstedt R, Gray D. (1998) Regulation of cytoplasmic, surface and soluble forms of CD40 ligand in mouse B cells. Eur J Immunol 28, 548-59.
47. Wang D, Freeman GJ, Levine H, Ritz J, Robertson MJ. (1997) Role of the CD40 and CD95 (APO-1/Fas) antigens in the apoptosis of human B-cell malignancies. Br J Haematol 97, 409-17.
48. Kamihira S, Yamada Y, Hirakata Y, Tsuruda K, Sugahara K, Tomonaga M, Maeda T, Tsukasaki K, Atogami S, Kobayashi N. (1997) Quantitative characterization and potential function of membrane Fas/APO-1 (CD95) receptors on leukaemic cells from chronic B and T lymphoid leukaemias. Br J Haematol 99, 858-65.
49. Hostager BS, Hsing Y, Harms DE, Bishop GA. (1996) Different CD40-mediated signaling events require distinct CD40 structural features. J Immunol 157, 1047-53.
50. Hsing Y, Bishop GA. (1999) Requirement for nuclear factor-kappaB activation by a distinct subset of CD40-mediated effector functions in B lymphocytes. J Immunol 162, 2804-11.
51. Vakkalanka RK, Woo C, Kirou KA, Koshy M, Berger D, Crow MK. (1999) Elevated levels and functional capacity of soluble CD40 ligand in systemic lupus erythematosus sera. Arthritis Rheum 42, 871-81.
52. Grammer AC, Bergman MC, Miura Y, Fujita K, Davis LS, Lipsky PE. (1995) The CD40 ligand expressed by human B cells costimulates B cell responses. Journal of Immunology 154, 4996-5010.
53. Carbone E, Ruggiero G, Terrazzano G, Palomba C, Manzo C, Fontana S, Spits H, Karre K, Zappacosta S. (1997) A new mechanism of NK cell cytotoxicity activation: the CD40-CD40 ligand interaction. J Exp Med 185, 2053-60.
54. Gauchat JF, Henchoz S, Mazzei G, Aubry JP, Brunner T, Blasey H, Life P, Talabot D, Flores-Romo L, Thompson J. et al. (1993) Induction of human IgE synthesis in B cells by mast cells and basophils. Nature 365, 340-3.
55. Mach F, Schonbeck U, Sukhova GK, Bourcier T, Bonnefoy JY, Pober JS, Libby P. (1997) Functional CD40 ligand is expressed on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for CD40-CD40 ligand signaling in atherosclerosis. Proc Natl Acad Sci U S A 94, 1931-6.
56. Henn V, Slupsky JR, Grafe M, Anagnostopoulos I, Forster R, Muller-Berghaus G, Kroczek RA. (1998) CD40 ligand on activated platelets triggers an inflammatory reaction of endothelial cells. Nature 391, 591-4.
57. Roy M, Waldschmidt T, Aruffo A, Ledbetter JA, Nolle RJ. (1993) The regulation of the expression of gp39, the CD40 ligand, on normal and cloned CD4+ T cells. J Immunol 151, 2497-510.
58. Pietravalle F, Lecoanet-Henchoz S, Blasey H, Aubry JP, Elson G, Edgerton MD, Bonnefoy JY, Gauchat JF. (1996) Human native soluble CD40L is a biologically active trimer, processed inside microsomes. J Biol Chem 271, 5965-7.
59. Graf D, Muller S, Korthauer U, van Kooten C, Weise C, Kroczek RA. (1995) A soluble form of TRAP (CD40 ligand) is rapidly released after T cell activation. Eur J Immunol 25, 1749-54.
60. Black RA, Rauch CT, Kozlosky CJ, Peschon JJ, Slack JL, Wolfson MF, Castner BJ, Stocking KL, Reddy P, Srinivasan S, Nelson N, Boiani N, Schooley KA, Gerhart M, Davis R, Fitzner JN, Johnson RS, Paxton RJ, March CJ, Cerretti DP. (1997) A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells. Nature 385, 729-33.
61. Moss ML, Jin SL, Milla ME, Bickett DM, Burkhart W, Carter HL, Chen WJ, Clay WC, Didsbury JR, Hassler D, Hoffman CR, Kost TA, Lambert MH, Leesnitzer MA, McCauley P, McGeehan G, Mitchell J, Moyer M, Pahel G, Rocque W, Overton LK, Schoenen F, Seaton T, Su JL, Becherer JD, et al. (1997) Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha. Nature 385, 733-6.
62. van Kooten C, Gaillard C, Galizzi JP, Hermann P, Fossiez F, Banchereau J, Blanchard D. (1994) B cells regulate expression of CD40 ligand on activated T cells by lowering the mRNA level and through the release of soluble CD40. Eur J Immunol 24, 787-92.
63. Dhein J, Walczak H, Baumler C, Debatin KM, Krammer PH. (1995) Autocrine T-cell suicide mediated by APO-1/(Fas/CD95). Nature 373, 438-41.
64. Dancescu M, Rubio-Trujillo M, Biron G, Bron D, Delespesse G, Sarfati M. (1992) Interleukin 4 protects chronic lymphocytic leukemic B cells from death by apoptosis and upregulates Bcl-2 expression. J Exp Med 176, 1319-26.
65. Foote LC, Marshak-Rothstein A, Rothstein TL. (1998) Tolerant B lymphocytes acquire resistance to Fas-mediated apoptosis after treatment with interleukin 4 but not after treatment with specific antigen unless a surface immunoglobulin threshold is exceeded. J Exp Med 187, 847-53.
66. Crawford DH, Catovsky D. (1993) In vitro activation of leukaemic B cells by interleukin-4 and antibodies to CD40. Immunology 80, 40-4.
67. Romano MF, Lamberti A, Tassone P, Alfinito F, Costantini S, Chiurazzi F, Defrance T, Bonelli P, Tuccillo F, Turco MC, Venuta S. (1998) Triggering of CD40 antigen inhibits fludarabine-induced apoptosis in B chronic lymphocytic leukemia cells. Blood 92, 990-5.
68. Furman RR, Asgary Z, Mascarenhas JO, Telford W, Liou H-C, Schattner EJ. Modulation of NF-κB activity and apoptosis in CLL B cells by CD40 engagement. (submitted manuscript).
69. Chandra J, Niemer I, Gilbreath J, Kliche KO, Andreeff M, Freireich EJ, Keating M, McConkey DJ. (1998) Proteasome inhibitors induce apoptosis in glucocorticoid-resistant chronic lymphocytic leukemic lymphocytes. Blood 92, 4220-9.
70. Yellin MJ, Lee JJ, Chess L, Lederman S. (1991) A human CD4-T cell leukemia subclone with contact-dependent helper function. Journal of Immunology 147, 3389-95.
71. Kato K, Cantwell MJ, Sharma S, Kipps TJ. (1998) Gene Transfer of CD40-ligand induces autologous immune recognition of chronic lymphocytic leukemia B cells. J Clin Invest 101, 1133-1141.
72. Schattner EJ, Mascarenhas J, Bishop J, Yoo DH, Chadburn A, Crow MK, Friedman SM. (1996) CD4+ T-cell induction of Fas-mediated apoptosis in Burkitt's lyrnphoma B cells. Blood 88, 1375-82.
73. Shokat KM, Goodnow CC. (1995) Antigen-induced B-cell death and elimination during germinal-centre immune responses. Nature 375, 334-8.
74. Pulendran B, Kannourakis G, Nouri S, Smith KG, Nossal GJ. (1995) Soluble antigen can cause enhanced apoptosis of germinal-centre B cells. Nature 375, 331-4.
75. Chen W, Wang H-G, Srinivasula SM, Alnemri ES, Cooper NR. (1999) B cell apoptosis triggered by antigen receptor ligation proceeds via a novel caspase-dependent pathway. J Immunol 163, 2483-2491.
76. Desai-Mehta A, Lu L, Ramsey-Goldman R, Datta SK. (1996) Hyperexpression of CD40 ligand by B and T cells in human lupus and its role in pathogenic autoantibody production. J Clin Invest 97, 2063-73.
77. Koshy M, Berger D, Crow MK. (1996) Increased expression of CD40 ligand on systemic lupus erythematosus lymphocytes. J Clin Invest 98, 826-37.
78. Cantwell M, Hua T, Pappas J, Kipps TJ. (1997) Acquired CD40-ligand deficiency in chronic lymphocytic leukemia. Nat Med 3, 984-9.
79. Saven A, Piro LD. (1994) 2-Chlorodeoxyadenosine: a newer purine analog active in the treatment of indolent lymphoid malignancies. Ann Intern Med 120, 784-91.
80. Tallman MS, Hakimian D. (1995) Purine nucleoside analogs: emerging roles in indolent lymphoproliferative disorders. Blood 86, 2463-74.
81. Damle RN, Wasil T, Fais F, Ghiotto F, Valetto A, Allen SL, Buchbinder A, Budman D, Dittmar K, Kolitz J, Lichtman SM, Schulman P, Vinciguerra VP, Rai KR, Ferrarini M, Chiorazzi N. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 94, 1840-7.
82. Hamlin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 94, 1848-54.
83. Rathmell JC, Townsend SE, Xu JC, Flavell RA, Goodnow CC. (1996) Expansion or elimination of B cells in vivo: dual roles for CD40-and Fas (CD95)-ligands modulated by the B cell antigen receptor. Cell 87, 319-29.
84. Rothstein TL. (1996) Signals and susceptibility to programmed death in B cells. Curr Opin Immunol 8, 362-71.
85. Raman C, Kuo A, Deshane J, Litchfield DW, Kimberly RP. (1998) Regulation of casein kinase 2 by direct interaction with cell surface receptor CD5. J Biol Chem 273, 19183-9.
86. Bikah G, Carey J, Ciallella JR, Tarakhovsky A, Bondada S. (1996) CD5-mediated negative regulation of antigen receptor-induced growth signals in B-1 B cells. Science 274, 1906-9.
87. Stamenkovic I, Seed B. (1988) CD19, the earliest differentiation antigen of the B cell lineage, bears three extracellular immunoglobulin-like domains and an Epstein-Barr virus-related cytoplasmic tail. J Exp Med 168, 1205-10.
88. Carter RH, Fearon DT. (1992) CD19: lowering the threshold for antigen receptor stimulation of B lymphocytes. Science 256, 105-7.
89. O'Rourke L, Tooze R, Fearon DT. (1997) Co-receptors of B lymphocytes. Curr Opin Immunol 9, 324-9.
90. Buhl AM, Pleiman CM, Rickert RC, Cambier JC. (1997) Qualitative regulation of B cell antigen receptor signaling by CD19: selective requirement for PI34-kinase activation, inositol-1,4,5-trisphosphate production and Ca2+ mobilization. J Exp Med 186, 1897-910.
91. Nadler LM, Stashenko P, Hardy R, Schlossman SF. (1980) A monoclonal antibody defining a lymphoma-associated antigen in man. J Immunol 125, 570-7.
92. Tedder TF, Streuli M, Schlossman SF, Saito H. (1988) Isolation and structure of a cDNA encoding the B1 (CD20) cell-surface antigen of human B lymphocytes. Proc Natl Acad Sci U S A 85, 208-12.
93. Tefferi A, Bartholmai BJ, Witzig TE, Li CY, Hanson CA, Phyliky RL. (1996) Heterogeneity and clinical relevance of the intensity of CD20 and immunoglobulin light-chain expression in B-cell chronic lymphocytic leukemia. Am J Clin Pathol 106, 457-61.
94. Camerini D, Walz G, Loenen WA, Borst J, Seed B. (1991) The T cell activation antigen CD27 is a member of the nerve growth factor/tumor necrosis factor receptor gene family. J Immunol 147, 3165-9.
95. Ranheim EA, Cantwell MJ, Kipps TJ. (1995) Expression of CD27 and its ligand, CD70, on chronic lymphocytic leukemia B cells. Blood 85, 3556-65.
96. Lens SM, Tesselaar K, van Oers MH, van Lier RA. (1998) Control of lymphocyte function through CD27-CD70 interactions. Semin Immunol 10, 491-9.
97. Uckun FM, Gajl-Peczalska K, Myers DE, Jaszcz W, Haissig S, Ledbetter JA. (1990) Temporal association of CD40 antigen expression with discrete stages of human B-cell ontogeny and the efficacy of anti-CD40 immunotoxins against clonogenic B-lineage acute lymphoblastic leukemia as well as B-lineage non-Hodgkin's lymphoma cells. Blood 76, 2449-56.
98. Goodwin RG, Alderson MR, Smith CA, Armitage RJ, Vanden Bos T, Jerzy R, Tough TW, Schoenborn MA, Davis-Smith T, Hennen K, et al. (1993) Molecular and biological characterization of a ligand for CD27 defines a new family of cytokines with homology to tumor necrosis factor. Cell 73, 447-56.
99. Cerutti A, Trentin L, Zambello R, Sancetta R, Milani A, Tassinari C, Adami F, Agostini C, Semenzato G. (1996) The CD5/CD72 receptor system is coexpressed with several functionally relevant counterstructures on human B cells and delivers a critical signaling activity. J Immunol 157, 1854-62.
100. Van de Velde H, von Hoegen I, Luo W, Parnes JR, Thielemans K. (1991) The B-cell surface protein CD72/Lyb-2 is the ligand for CD5. Nature 351, 662-5.
101. Reth M. (1995) The B-cell antigen receptor complex and co-receptors. Immunol Today 16, 310-3.
102. Pleiman CM, D DA, Cambier JC. (1994) The B-cell antigen receptor complex: structure and signal transduction. Immunol Today 15, 393-9.
103. Thompson AA, Talley JA, Do HN, Kagan HL, Kunkel L, Berenson J, Cooper MD, Saxon A, Wall R. (1997) Aberrations of the B-cell receptor B29 (CD79b) gene in chronic lymphocytic leukemia. Blood 90, 1387-94.
104. Yokochi T, Holly RD, Clark EA. (1982) B lymphoblast antigen (BB-1) expressed on Epstein-Barr virus-activated B cell blasts, B lymphoblastoid cell lines, and Burkitt's lymphomas. J Immunol 128, 823-7.
105. Freedman AS, Freeman G, Horowitz JC, Daley J, Nadler LM. (1987) B7, a B-cell-restricted antigen that identifies preactivated B cells. J Immunol 139, 3260-7.
106. Lenschow DJ, Walunas TL, Bluestone JA. (1996) CD28/B7 system of T cell costimulation. Annu Rev Immunol 14, 233-58.
107. Cerutti A, Schaffer A, Shah S, Zan H, Liou HC, Goodwin RG, Casali P. (1998) CD30 is a CD40-inducible molecule that negatively regulates CD40-mediated immunoglobulin class switching in non-antigen-selected human B cells. Immunity 9, 247-56.
108. Trentin L, Zambello R, Agostini C, Enthammer C, Cerutti A, Adami F, Zamboni S, Semenzato G. (1994) Expression and regulation of tumor necrosis factor, interleukin-2, and hematopoietic growth factor receptors in B-cell chronic lymphocytic leukemia. Blood 84, 4249-56.
109. Lens SM, Tesselaar K, den Drijver BF, van Oers MH, van Lier RA. (1996) A dual role for both CD40-ligand and TNF-alpha in controlling human B cell death. J Immunol 156, 507-14.
110. Baker SJ, Reddy EP. (1998) Modulation of life and death by the TNF receptor superfamily. Oncogene 17, 3261-70.
111. Cordingley FT, Bianchi A, Hoffbrand AV, Reittie JE, Heslop HE, Vyakarnam A, Turner M, Meager A, Brenner MK. (1988) Tumour necrosis factor as an autocrine tumour growth factor for chronic B-cell malignancies. Lancet 1, 969-71.
112. Heslop HE, Bianchi AC, Cordingley FT, Turner M, Chandima W, De Mel CP, Hoffbrand AV, Brenner MK. (1990) Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders. J Exp Med 172, 1729-34.
113. Jabbar SA, Hoffbrand AV, Gitendra Wickremasinghe R. (1994) Regulation of transcription factors NF kappa B and AP-1 following tumour necrosis factor-alpha treatment of cells from chronic B cell leukaemia patients. Br J Haematol 86, 496-504.